4D Molecular Therapeutics Inc Stock

$3.01

8.38% today

Nasdaq, Apr 03, 06:48 pm CET

ISIN

US35104E1001

Symbol

FDMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

4D Molecular Therapeutics Inc Stock price

$3.28

-19.72 85.74% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

+0.29 9.70%

ISIN

US35104E1001

Symbol

FDMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$151.87m
Enterprise Value	$-248.40m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	1.80
EV/Sales (TTM) EV/Sales	-6,210.00
P/S ratio (TTM) P/S ratio	3,796.75
P/B ratio (TTM) P/B ratio	0.29
Revenue (TTM) Revenue	$40.00k
EBIT (operating result TTM) EBIT	$-187.84m
Free Cash Flow (TTM) Free Cash Flow	$-138.37m
Cash position	$424.88m
EPS (TTM) EPS	$-3.16
P/E forward	negative
P/S forward	39.07
EV/Sales forward	negative
Short interest	11.30%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

4D Molecular Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

9x Buy

75%

2x Hold

17%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

Buy

75%

Hold

17%

Sell

Analyst Estimates with Stock Price Targets

Financial data from 4D Molecular Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	0.04 0.04	- 100%
- Direct Costs	6.71 6.71	- 16,775%
Gross Profit	-6.67 -6.67	- -16,675%
- Selling and Administrative Expenses	33 33	- 82,925%
- Research and Development Expense	141 141	- 353,250%
EBITDA	-181 -181	- -452,850%
- Depreciation and Amortization	6.71 6.71	- 16,775%
EBIT (Operating Income) EBIT	-188 -188	- -469,603%
Net Profit	-161 -161	- -402,175%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

4D Molecular Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

7 days ago

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC ...

Neutral

GlobeNewsWire

●

24 days ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the ...

Neutral

GlobeNewsWire

●

about one month ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

EMERYVILLE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2024 financial results, provided operational highlights and outl...

More 4D Molecular Therapeutics Inc News

Company Profile

4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for optalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Head office	United States
CEO	David Kirn
Employees	227
Founded	2013
Website	www.4dmoleculartherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now